SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun
2019 - 2018 - 2017 - 2016

June 2019 Autoimmune News

Exploring New Treatments for Autoimmune Diseases A new grant will allow Michigan Medicine researchers to explore personalized approaches to treating autoimmune diseases such as scleroderma, lupus, rheumatoid arthritis and others. M Health Lab, 05/01/2019. (Also see Arthritis Treatments - General)

Human papillomavirus vaccination and the risk of autoimmune disorders: A systematic review and meta –analysis. No evidence of an association between HPV vaccination and ADs was found. PubMed, Vaccine, 04/26/2019. (Also see Vaccinations and Scleroderma and Causes of Scleroderma: Vaccinations)

Rheumatoid arthritis patients' oral health and disease activity. Cooperation between rheumatologists and dentists is important in oral health management in periodontal inflammation. PubMed, Int J Rheum Dis, 05/07/2019. (Also see Symptoms and Complications of Rheumatoid Arthritis and Periodontal Disease)

Differential synovial tissue (ST) biomarkers among psoriatic arthritis and rheumatoid factor/anti–citrulline antibody–negative rheumatoid arthritis. Histological analysis of ST may help to solve the clinical overlap between the two diseases and provides prognostic data about the therapy success. PubMed, Arthritis Res Ther, 2019 May 9;21(1):116. (Also see Diagnosis of Rheumatoid Arthritis and Psoriasis and Psoriatic Arthritis)

Evaluation of response criteria in rheumatoid arthritis treated with biological disease–modifying antirheumatic drugs. EULAR response criteria overestimate the response under Interleukin-6 inhibitors treatment because the acute–phase reactants improvement largely contributes to the Disease Activity Score 28 improvement. PubMed, Arthritis Care Res (Hoboken), 05/06/2019. (Also see Biologic Agents)

A Meta–Analysis of Treatment for Primary Sjögren's Syndrome. Reducing inflammation potentially improves salivary gland function. No individual immunomodulatory drug demonstrated consistent benefit in xerostomia and xerophthalmia. PubMed, Arthritis Care Res (Hoboken), 05/06/2019. (Also see Treatments for Symptoms of Sjögren's Syndrome)

Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus (SLE) and lupus nephritis (LN). These results indicate that for active LN, sTNF-R1 could be a useful serum cytokine marker, with potential for vascular endothelial growth factor in the urine. PubMed, Lupus, 2019 May 2:961203319845487. (Also see Diagnosis of Lupus and Interleukins)

High levels of circulating interferons (IFNs) type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Our findings suggest that IFNs contribute to the heterogeneity of clinical manifestations in SLE, and measuring circulating IFNs could assist in designing clinical trials with therapies targeting IFN pathways. PubMed, Arthritis Res Ther, 2019 Apr 29;21(1):107. (Also see Diagnosis of Lupus)

T cell receptor β repertoires (TCR) as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. These characteristics of the TCR repertoire can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases. PubMed, Ann Rheum Dis, 05/17/2019. (Also see Diagnosis of Lupus and Diagnosis of Rheumatoid Arthritis)

Prognostic Value of Microscopic Hematuria after Induction of Remission in Antineutrophil Cytoplasmic Antibodies–Associated Vasculitis. Hematuria at remission after a first pauci–immune glomerulonephritis flare was not associated with end–stage renal disease but with the occurrence of renal relapse within 44 months of remission. PubMed, Am J Nephrol, 2019 May 22;49(6):479-486. (Also see Vasculitis)

Go to Autoimmune News: May 2019
 

Many thanks to our recent donors, Jack and Elizabeth Lewis. See ISN News for more donors. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!

DONATE